Skip to content

Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis

Research output: Contribution to journalArticle

Standard

Prevalence and burden of HBV co-infection among people living with HIV : A global systematic review and meta-analysis. / Platt, Lucy; French, Clare E; McGowan, Catherine R.; Sabin, Keith; Gower, Erin; Trickey, Adam; McDonald, Bethan; Ong, Jason; Stone, Jack; Easterbrook, Philippa J; Vickerman, Peter.

In: Journal of Viral Hepatitis, 22.12.2019.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Platt, Lucy ; French, Clare E ; McGowan, Catherine R. ; Sabin, Keith ; Gower, Erin ; Trickey, Adam ; McDonald, Bethan ; Ong, Jason ; Stone, Jack ; Easterbrook, Philippa J ; Vickerman, Peter. / Prevalence and burden of HBV co-infection among people living with HIV : A global systematic review and meta-analysis. In: Journal of Viral Hepatitis. 2019.

Bibtex

@article{2e196cecc9184fe19cc47415dbb0efa4,
title = "Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis",
abstract = "Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV‐HBsAg co‐infection is unknown. We undertook a systematic review to estimate the global burden of HBsAg co‐infection in PLHIV. We searched MEDLINE, Embase and other databases for published studies (2002‐2018) measuring prevalence of HBsAg among PLHIV. The review was registered with PROSPERO (#CRD42019123388). Populations were categorized by HIV‐exposure category. The global burden of co‐infection was estimated by applying regional co‐infection prevalence estimates to UNAIDS estimates of PLHIV. We conducted a meta‐analysis to estimate the odds of HBsAg among PLHIV compared to HIV‐negative individuals. We identified 506 estimates (475 studies) of HIV‐HBsAg co‐infection prevalence from 80/195 (41.0{\%}) countries. Globally, the prevalence of HIV‐HBsAg co‐infection is 7.6{\%} (IQR 5.6{\%}‐12.1{\%}) in PLHIV, or 2.7 million HIV‐HBsAg co‐infections (IQR 2.0‐4.2). The greatest burden (69{\%} of cases; 1.9 million) is in sub‐Saharan Africa. Globally, there was little difference in prevalence of HIV‐HBsAg co‐infection by population group (approximately 6{\%}‐7{\%}), but it was slightly higher among people who inject drugs (11.8{\%} IQR 6.0{\%}‐16.9{\%}). Odds of HBsAg infection were 1.4 times higher among PLHIV compared to HIV‐negative individuals. There is therefore, a high global burden of HIV‐HBsAg co‐infection, especially in sub‐Saharan Africa. Key prevention strategies include infant HBV vaccination, including a timely birth‐dose. Findings also highlight the importance of targeting PLHIV, especially high‐risk groups for testing, catch‐up HBV vaccination and other preventative interventions. The global scale‐up of antiretroviral therapy (ART) for PLHIV using a tenofovir‐based ART regimen provides an opportunity to simultaneously treat those with HBV co‐infection, and in pregnant women to also reduce mother‐to‐child transmission of HBV alongside HIV.",
keywords = "systematic review, HIV, viral hepatitis, co-infection, hepatitis B",
author = "Lucy Platt and French, {Clare E} and McGowan, {Catherine R.} and Keith Sabin and Erin Gower and Adam Trickey and Bethan McDonald and Jason Ong and Jack Stone and Easterbrook, {Philippa J} and Peter Vickerman",
year = "2019",
month = "12",
day = "22",
doi = "10.1111/jvh.13217",
language = "English",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Prevalence and burden of HBV co-infection among people living with HIV

T2 - A global systematic review and meta-analysis

AU - Platt, Lucy

AU - French, Clare E

AU - McGowan, Catherine R.

AU - Sabin, Keith

AU - Gower, Erin

AU - Trickey, Adam

AU - McDonald, Bethan

AU - Ong, Jason

AU - Stone, Jack

AU - Easterbrook, Philippa J

AU - Vickerman, Peter

PY - 2019/12/22

Y1 - 2019/12/22

N2 - Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV‐HBsAg co‐infection is unknown. We undertook a systematic review to estimate the global burden of HBsAg co‐infection in PLHIV. We searched MEDLINE, Embase and other databases for published studies (2002‐2018) measuring prevalence of HBsAg among PLHIV. The review was registered with PROSPERO (#CRD42019123388). Populations were categorized by HIV‐exposure category. The global burden of co‐infection was estimated by applying regional co‐infection prevalence estimates to UNAIDS estimates of PLHIV. We conducted a meta‐analysis to estimate the odds of HBsAg among PLHIV compared to HIV‐negative individuals. We identified 506 estimates (475 studies) of HIV‐HBsAg co‐infection prevalence from 80/195 (41.0%) countries. Globally, the prevalence of HIV‐HBsAg co‐infection is 7.6% (IQR 5.6%‐12.1%) in PLHIV, or 2.7 million HIV‐HBsAg co‐infections (IQR 2.0‐4.2). The greatest burden (69% of cases; 1.9 million) is in sub‐Saharan Africa. Globally, there was little difference in prevalence of HIV‐HBsAg co‐infection by population group (approximately 6%‐7%), but it was slightly higher among people who inject drugs (11.8% IQR 6.0%‐16.9%). Odds of HBsAg infection were 1.4 times higher among PLHIV compared to HIV‐negative individuals. There is therefore, a high global burden of HIV‐HBsAg co‐infection, especially in sub‐Saharan Africa. Key prevention strategies include infant HBV vaccination, including a timely birth‐dose. Findings also highlight the importance of targeting PLHIV, especially high‐risk groups for testing, catch‐up HBV vaccination and other preventative interventions. The global scale‐up of antiretroviral therapy (ART) for PLHIV using a tenofovir‐based ART regimen provides an opportunity to simultaneously treat those with HBV co‐infection, and in pregnant women to also reduce mother‐to‐child transmission of HBV alongside HIV.

AB - Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV‐HBsAg co‐infection is unknown. We undertook a systematic review to estimate the global burden of HBsAg co‐infection in PLHIV. We searched MEDLINE, Embase and other databases for published studies (2002‐2018) measuring prevalence of HBsAg among PLHIV. The review was registered with PROSPERO (#CRD42019123388). Populations were categorized by HIV‐exposure category. The global burden of co‐infection was estimated by applying regional co‐infection prevalence estimates to UNAIDS estimates of PLHIV. We conducted a meta‐analysis to estimate the odds of HBsAg among PLHIV compared to HIV‐negative individuals. We identified 506 estimates (475 studies) of HIV‐HBsAg co‐infection prevalence from 80/195 (41.0%) countries. Globally, the prevalence of HIV‐HBsAg co‐infection is 7.6% (IQR 5.6%‐12.1%) in PLHIV, or 2.7 million HIV‐HBsAg co‐infections (IQR 2.0‐4.2). The greatest burden (69% of cases; 1.9 million) is in sub‐Saharan Africa. Globally, there was little difference in prevalence of HIV‐HBsAg co‐infection by population group (approximately 6%‐7%), but it was slightly higher among people who inject drugs (11.8% IQR 6.0%‐16.9%). Odds of HBsAg infection were 1.4 times higher among PLHIV compared to HIV‐negative individuals. There is therefore, a high global burden of HIV‐HBsAg co‐infection, especially in sub‐Saharan Africa. Key prevention strategies include infant HBV vaccination, including a timely birth‐dose. Findings also highlight the importance of targeting PLHIV, especially high‐risk groups for testing, catch‐up HBV vaccination and other preventative interventions. The global scale‐up of antiretroviral therapy (ART) for PLHIV using a tenofovir‐based ART regimen provides an opportunity to simultaneously treat those with HBV co‐infection, and in pregnant women to also reduce mother‐to‐child transmission of HBV alongside HIV.

KW - systematic review

KW - HIV

KW - viral hepatitis

KW - co-infection

KW - hepatitis B

U2 - 10.1111/jvh.13217

DO - 10.1111/jvh.13217

M3 - Article

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

ER -